Moleculin announced the exercise of warrants that will generate $8.3 million in gross proceeds. This financing method enables the biotech company to secure capital from previous investors while minimizing immediate share dilution. Moleculin continues to focus on its lead asset, annamycin, in its oncology clinical programs.
CoinShares has launched the $BNB Staking Exchange-Traded Product (ETP), which offers regulated access to staking rewards with no associated fees. This move aligns with the growing trend in Europe of regulated ETPs that integrate staking […]
Onchain investigator ZachXBT announced on social media that he will release a significant investigation on February 26 into a leading crypto business, with allegations of several employees misusing internal data for insider trading. Polymarket data […]
Brett Tejpaul, Co-CEO of Coinbase Institutional, is set to join Phong Le, President and CEO of Strategy, at Strategy World 2026 to discuss how tokenization is transforming corporate finance. This discussion comes as tokenization, which […]